TY  - GEN
AU  - Wülfing,C
AU  - Bierer,S
AU  - Bögemann,M
AU  - Piechota,H
AU  - Hertle,L
TI  - [Therapy of hormone refractory prostate cancer: new standards, new trends]
SN  - 0001-7868
PY  - 2006///0623
KW  - Angiogenesis Inhibitors
KW  - administration & dosage
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents
KW  - Antineoplastic Agents, Hormonal
KW  - therapeutic use
KW  - Antineoplastic Agents, Phytogenic
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Clinical Trials, Phase I as Topic
KW  - Clinical Trials, Phase II as Topic
KW  - Clinical Trials, Phase III as Topic
KW  - Diphosphonates
KW  - Docetaxel
KW  - Drug Resistance, Neoplasm
KW  - Endothelin Receptor Antagonists
KW  - Humans
KW  - Male
KW  - Meta-Analysis as Topic
KW  - Mitoxantrone
KW  - Mutation
KW  - Oligonucleotides, Antisense
KW  - Patient Selection
KW  - Prostatic Neoplasms
KW  - drug therapy
KW  - Protein-Tyrosine Kinases
KW  - antagonists & inhibitors
KW  - Quality of Life
KW  - Randomized Controlled Trials as Topic
KW  - Receptors, Androgen
KW  - genetics
KW  - Taxoids
KW  - Time Factors
KW  - Trastuzumab
N1  - Publication Type: Comparative Study; Journal Article; Review
UR  - https://doi.org/10.1055/s-2004-830209
ER  -